Crimean-Congo hemorrhagic fever virus M-segment nucleic acid vaccine and methods of use and production

Patent metadata

Field	Value
Publication number	US-12576145-B2
Application number	US-202118029576-A
Country	US
Kind code	B2
Filing date	Sep 30, 2021
Priority date	Sep 30, 2020
Publication date	Mar 17, 2026
Grant date	Mar 17, 2026

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Here, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene (GPC) of the laboratory CCHFV strain CCHFV-IbAr 10200 (CCHFV-M10200). Increasing the dose of CCHFV-M 10200 provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant, heterologous CCHFV-Afg09-2990 strain. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 GPC expressing DNA vaccine (CCHFV-M Afgog). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.

First claim

We claim:

1 . A vaccine comprising a vector comprising a promoter and the nucleic acid of SEQ ID NO: 3, the nucleic acid of SEQ ID NO: 3 being operably linked to the promoter.

2 . The vaccine of claim 1 , wherein the vector comprises the nucleic acid of SEQ ID NO: 4.

3 . The vaccine of claim 1 , wherein the vaccine further comprises an effective amount of an adjuvant.

4 . The vaccine of claim 1 , wherein the vaccine further comprises a pharmaceutically acceptable substance.

5 . A method comprising administering a vaccine comprising a vector comprising a promoter and the nucleic acid of SEQ ID NO: 3, the nucleic acid of SEQ ID NO: 3 being operably linked to the promoter.

6 . The method of claim 5 , wherein the vector comprises the nucleic acid of SEQ ID NO: 4.

7 . A method of increasing the likelihood of survival or decreasing the likelihood or severity of at least one symptom from a Congo-Crimean Hemorrhagic Fever Virus (CCHFV) in a subject in need thereof, the method comprising administering to the subject a vaccine comprising a vector comprising a promoter and 8.5 μmoles or more of the nucleic acid of SEQ ID NO: 1, wherein the nucleic acid of SEQ ID NO: 1 is operably linked to the promoter and wherein the administering provides at least a 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.8%, 99.9%, or 100% likelihood of survival in the subject five days after exposure to the CCHFV or the administering reduces the likelihood of a greater than 10% weight loss in the subject after exposure to the CCHFV.

8 . The method of claim 7 , wherein the administering comprises three doses of the vaccine, at least two of the doses being spaced at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days apart and each dose comprising 8.5 μmoles or more of the nucleic acid of SEQ ID NO: 1.

9 . The method of claim 7 , wherein the CCHFV is from Clade I, II, III, IV, V, VI, or VII.

10 . The method of claim 7 , wherein the CCHFV comprises IbAr 10200 or Afg09-2990.

11 . A method of increasing the likelihood of survival or decreasing the likelihood or severity of at least one symptom from a Congo-Crimean Hemorrhagic Fever Virus (CCHFV) in a subject in need thereof, the method comprising administering to the subject a vaccine comprising a vector comprising 8.5 μmoles or more of the nucleic acid of SEQ ID NO: 3, and a promoter, wherein the nucleic acid of SEQ ID NO: 3 is operably linked to the promoter and wherein the administering provides at least a 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.8%, 99.9%, or 100% likelihood of survival in the subject five days after exposure to the CCHFV or the administering reduces the likelihood of a greater than 10% weight loss in the subject after exposure to the CCHFV.

12 . The method of claim 11 , wherein the administering comprises three doses of the vaccine, each dose being spaced at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days apart and each dose comprising 8.5 μmoles or more of the nucleic acid of SEQ ID NO: 3.

13 . The method of claim 11 , wherein the CCHFV is from Clade I, II, III, IV, V, VI, or VII.

14 . The method of claim 11 , wherein the CCHFV comprises IbAr 10200 or Afg09-2990.

15 . A method of increasing the likelihood of survival or decreasing the likelihood or severity of at least one symptom from a Congo-Crimean Hemorrhagic Fever Virus (CCHFV) in a subject in need thereof, the method comprising administering to the subject a vaccine comprising a vector comprising a promoter and 0.385 μmoles or more of the nucleic acid of SEQ ID NO: 1 or SEQ ID NO: 3 per 1 gram of body weight of the subject, wherein the nucleic acid of SEQ ID NO: 1 or SEQ ID NO: 3 is operably linked to the promoter and wherein the administering provides at least a 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.8%, 99.9%, or 100% likelihood of survival in the subject five days after exposure to the CCHFV or the administering reduces the likelihood of a greater than 10% weight loss in the subject after exposure to the CCHFV.

16 . The method of claim 15 , wherein the administering comprises three doses of the vaccine, at least two of the doses being spaced at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days apart and each dose comprising 0.385 μmoles or more of the nucleic acid of SEQ ID NO: 1 per 1 gram of body weight of the subject.

17 . The method of claim 15 , wherein the CCHFV is from Clade I, II, III, IV, V, VI, or VII.

18 . The method of claim 15 , wherein the CCHFV comprises IbAr 10200 or Afg09-2990.

19 . The method of claim 15 , wherein the administering comprises three doses of the vaccine, each dose being spaced at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days apart and each dose comprising 0.385 μmoles or more of the nucleic acid of SEQ ID NO: 3 per 1 gram of body weight of the subject.

20 . The method of claim 15 , wherein the CCHFV is from Clade I, II, III, IV, V, VI, or VII.

21 . The method of claim 15 , wherein the CCHFV comprises IbAr 10200 or Afg09-2990.

22 . A method of increasing the likelihood of survival or decreasing the likelihood or severity of at least one symptom from a Congo-Crimean Hemorrhagic Fever Virus (CCHFV) in a subject in need thereof, the method comprising administering to the subject an effective amount of a vaccine comprising a vector comprising a promoter and the nucleic acid of SEQ ID NO: 1, wherein the nucleic acid of SEQ ID NO: 1 is operably linked to the promoter and wherein the administering provides at least a 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.8%, 99.9%, or 100% likelihood of survival in the subject five days after exposure to the CCHFV or the administering reduces the likelihood of a greater than 10% weight loss in the subject after exposure to the CCHFV.

23 . The method of claim 22 , wherein the CCHFV is not IbAr 10200.

24 . The method of claim 22 , wherein the administering comprises three doses of the vaccine, each dose being spaced at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days apart.

25 . The method of claim 22 , wherein the CCHFV is from Clade I, II, III, IV, V, VI, or VII.

26 . The method of claim 22 , wherein the CCHFV comprises Afg09-2990.

27 . The method of claim 22 , wherein the effective amount comprises 0.385 μmoles or more of the nucleic acid of SEQ ID NO: 1 per 1 gram of body weight of the subject.

Assignees

• Us Gov Sec Army

Inventors

• Garrison Aura R
• Shoemaker Charles J
• Suschak Iii John J

Classifications

• C12N2760/12034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K2039/572

  cytotoxic response · CPC title